Orchid Pharma Limited has informed the Exchange regarding Change in Auditors of the company.
ORCHPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Orchid Pharma reported standalone profit of Rs 4,520.79 lakhs for FY 2026, down significantly from Rs 10,648.34 lakhs in FY 2025. Consolidated profit stood at Rs 2,054.70 lakhs versus Rs 9,965.68 lakhs in the previous year. The company's auditors Singhi & Co. issued an unmodified opinion on standalone results but a qualified opinion on consolidated results due to three unaudited US subsidiaries (Orchid Pharmaceuticals Inc., Bexel Pharmaceuticals Inc., and Diakron Pharmaceuticals Inc.). The Board also approved appointment of an internal auditor for FY 2026-27 and noted pending amalgamation with Dhanuka Laboratories Limited awaiting NCLT approval. The company completed acquisitions of Allecra Therapeutics in Germany and France in 2025, gaining full ownership of Enmetazobactam (EXBLIFEP).
The sharp decline in profitability and qualified audit opinion on consolidated results may raise concerns among investors. The unaudited US subsidiaries create uncertainty in consolidated financials. However, the company remains profitable on standalone basis and continues strategic expansion with the Allecra acquisition.